Patients with muscle-invasive and high-risk non-muscle invasive urothelial carcinoma of bladder who undergo radical cystectomy (RC) and lymphadenectomy are closely monitored for recurrence. The risk of disease recurrence is highest during the first few years. Defining late recurrence patterns is critical for designing optimal surveillance and management strategies. A recent study published by Yoo et […]
Athens, Greece (Urotoday.com) Dr. Badrinath Konety presented on intravesical therapy for non-muscle invasive bladder cancer (NMIBC). The current risk-based therapy entails: Low risk – surveillance or mitomycin Intermediate risk – mitomycin or BCG High risk – BCG (and mitomycin as a second choice) 15 years after treatment, 37%, 27% and 34% of patients with high-risk superficial […]
Athens, Greece (Urotoday.com) In this talk, Dr. Tilki reviewed several prognostic biomarkers in the setting of localized prostate cancer management. The currently available prognostic biomarkers include: Oncotype Dx (GPS) Prolaris Decipher Decipher Biopsy According to the EAU guidelines, the results of prospective multicenter studies are awaited before a recommendation can be made regarding the routine application of currently available prognostic biomarkers. This […]
Athens, Greece (UroToday.com) Dr. Ashish Kamat presented on the important concept of restaging transurethral resection of the bladder tumor (TURBT). There has bee some discussion in the past regarding the need to perform another TURBT after the initial one, which is called the restaging TURBT (re-TURBT). Table 1 demonstrates the current recommendation by the various large […]
Athens, Greece (UroToday.com) In his presentation, Dr. Laurence Klotz discussed the recent development in imaging prior to a prostate biopsy. With Gleason grade group 1 (GG1), the goal of monitoring is to identify the presence of higher-grade cancer. With Gleason grade group 2 (GG2) triggers for intervention are not so obvious. The PROMIS study was a […]
{{header-clinical-trials-navigation}} 18F-Fluciclovine PET CT as an Indicator of Therapeutic Response in Metastatic Prostate Carcinoma (M1PCa) Condition: Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT04134208 Sponsor: M.D. Anderson Cancer Center Phase: Phase 4 Eligibility: Age: minimum 18 Years maximum N/A Gender: Male Inclusion Criteria: Histologically or […]
Radiotherapy is the standard salvage treatment after radical prostatectomy. To date, the role of androgen deprivation therapy has not been formally shown. In this follow-up study, we aimed to update the results of the GETUG-AFU 16 trial, which assessed the efficacy of radiotherapy plus androgen suppression versus radiotherapy alone. GETUG-AFU 16 was an open-label, multicentre, […]
To compare a standard radio-oncological and a surgical biochemical failure definition after combined-modality radiation therapy (CRT) in men with intermediate- and high-risk prostate cancer. 425 men were treated with external beam radiotherapy (59. 4 Gy, 33 fractions) and 125J seed-brachytherapy (S-BT, 100 Gy). Biochemical recurrence (BR) was defined either as radio-oncologic (rBR), using a +2 ng/mL prostate-specific antigen (PSA) […]
DNA sequencing has become less expensive and patients are requesting sequence information more often. The clinical utility of identifying genomic and/or somatic mutations remains uncertain in most cancers and especially in prostate cancer. However, clinical guidelines must offer guidance. The rapidly expanding knowledge base requires that guideline panels pay vigilant attention to the literature, advocate […]
To identify a subset of men with Gleason score (GS) 6 prostate cancer who are at high risk for upgrading/upstaging who should be recommended for multiparametric magnetic resonance imaging. Between 1992 and 2017, a total of 3571 men with GS6 prostate cancer were consecutively treated at a single institution with radical prostatectomy. Logistic regression multivariable […]
